Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
0.900
-0.068 (-7.05%)
At close: Apr 28, 2026, 4:00 PM EDT
0.901
+0.001 (0.06%)
After-hours: Apr 28, 2026, 7:50 PM EDT
Company Description
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments.
The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer.
It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies.
Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Oncolytics Biotech Inc.
| Country | Canada |
| Founded | 1998 |
| IPO Date | Nov 8, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Jared Kelly |
Contact Details
Address: 322 11th Avenue SW, Suite 804 Calgary, AB T2R 0C5 Canada | |
| Phone | 403 670 7377 |
| Website | oncolyticsbiotech.com |
Stock Details
| Ticker Symbol | ONCY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001129928 |
| CUSIP Number | 68237V103 |
| ISIN Number | US68237V1035 |
| Employer ID | 98-0541667 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jared Kelly J.D., L.L.M. | Chief Executive Officer and Director |
| Kirk J. Look C.A., CPA | Chief Financial Officer |
| Dr. Thomas C. Heineman M.D., Ph.D. | Chief Medical Officer |
| John McAdory | Executive Vice President of Strategy and Operations |
| Allison Hagerman P.Eng., P.M.P. | Chief Technology Officer |
| Jon Patton | Director of Investor Relations and Communication |
| Andrew P. Aromando | Chief Business Officer |
| Yujun Wu | Vice President and Head of Biostatistics |
| John Mark Lievonen B.B.A., CM, F.C.A., FCPA, LLD, M.B.A. | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | 8-K | Current Report |
| Apr 8, 2026 | F-10POS | Filing |
| Apr 8, 2026 | F-10POS | Filing |
| Apr 8, 2026 | F-10POS | Filing |
| Apr 8, 2026 | F-10POS | Filing |
| Apr 8, 2026 | F-10POS | Filing |
| Apr 8, 2026 | F-10POS | Filing |
| Apr 8, 2026 | F-10POS | Filing |
| Apr 8, 2026 | F-10POS | Filing |
| Apr 8, 2026 | F-10POS | Filing |